Evidence regarding SGLT2 inhibitors for the management of diabetic dyslipidemia
We read with interest the article by Puri et al. entitled, “Management of diabetic dyslipidemia in Indians: Expert consensus statement from the Lipid Association of India”. The article states that more than half of the patients with diabetes have a high risk of dyslipidemia, resulting in an accelerated risk of atherosclerotic cardiovascular disease (ASC VD). The authors thereby release a consensus statement from the Lipid Association of India (LAI) for the management of diabetic dyslipidemia. This statement discusses the effects of lipid lowering drugs such as statins/ezetimibe, sodium-glucose transport protein 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for diabetic dyslipidemia.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Rajmohan Seetharaman, Shirish S. Joshi Tags: Letter to the Editor Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Diabetes | Endocrinology | Heart | India Health | Lipidology | SGLT2 Inhibitors | Sodium | Statin Therapy | Vytorin | Zetia